Craig-Hallum analyst Matthew Hewitt lowered the firm’s price target on BioLife Solutions to $21 from $23 and keeps a Buy rating on the shares following the Q3 results. BioLife is on the verge of a transformation, and believes the current valuation does not give BioLife enough credit for the potential growth the company could capture in the C> market, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLFS:
- BioLife Solutions price target lowered to $15 from $25 at Lake Street
- BioLife Solutions still sees 2023 revenue at low end of $144M-$158M
- BioLife Solutions reports Q3 EPS (67c), consensus (38c)
- BioLife Solutions Reports Third Quarter 2023 Financial Results
- BLFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
